Fierce Pharma Asia—Astellas CEO’s 5-year plan; Takeda’s psoriasis win; RA’s China bridge program

Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. | Astellas CEO explained to Fierce the company's new five-year plan. A Takeda candidate beat Bristol Myers Squibb's Sotyktu in a head-to-head psoriasis trial. RA Capital is offering China capabilities to its portfolio companies through a one-year-old initiative. And more.